GlcNAc6ST-1 regulates sulfation of N-glycans and myelination in the peripheral nervous system

Highly specialized glial cells wrap axons with a multilayered myelin membrane in vertebrates. Myelin serves essential roles in the functioning of the nervous system. Axonal degeneration is the major cause of permanent neurological disability in primary myelin diseases. Many glycoproteins have been identified in myelin, and a lack of one myelin glycoprotein results in abnormal myelin structures in many cases. However, the roles of glycans on myelin glycoproteins remain poorly understood. Here, we report that sulfated N-glycans are involved in peripheral nervous system (PNS) myelination. PNS myelin glycoproteins contain highly abundant sulfated N-glycans. Major sulfated N-glycans were identified in both porcine and mouse PNS myelin, demonstrating that the 6-O-sulfation of N-acetylglucosamine (GlcNAc-6-O-sulfation) is highly conserved in PNS myelin between these species. P0 protein, the most abundant glycoprotein in PNS myelin and mutations in which at the glycosylation site cause Charcot-Marie-Tooth neuropathy, has abundant GlcNAc-6-O-sulfated N-glycans. Mice deficient in N-acetylglucosamine-6-O-sulfotransferase-1 (GlcNAc6ST-1) failed to synthesize sulfated N-glycans and exhibited abnormal myelination and axonal degeneration in the PNS. Taken together, this study demonstrates that GlcNAc6ST-1 modulates PNS myelination and myelinated axonal survival through the GlcNAc-6-O-sulfation of N-glycans on glycoproteins. These findings may provide novel insights into the pathogenesis of peripheral neuropathy.

Rapid and efficient action potential propagation in vertebrates depends on axon ensheathment by a multilayered membrane called myelin. Myelin, which is formed by Schwann cells in the peripheral nervous system (PNS) and by oligodendrocytes in the central nervous system (CNS), enwraps axons in segments that are separated by the nodes of Ranvier. Recent studies have revealed that myelination tunes axonal functions, and vice versa. Degeneration of demyelinated axons is a major cause of permanent neurological disability in primary human myelin diseases. Glycoproteins are prominent components of plasma membranes, and as such, many glycoproteins have been identified in myelin where they play important roles in the formation, maintenance and
degeneration of myelin sheaths7–9. However, the precise structures and roles of glycans on myelin glycoproteins remain largely unknown. Even though cell surface glycosylation is one of the key features universal to all eukaryotic cells, the degree of evolutionary conservation of glycans between taxa is very low in contrast to that of genetic and protein sequences10. Although the core structures of most types of glycans tend to be conserved across various taxa, within different mammalian species glycan structure is diverse11. However, interspecific comparative analyses of glycan structures have not been described in detail.

Circulating antibodies directed against specific glycoconjugates are associated with a variety of diseases, including Guillain-Barré syndrome, Fisher syndrome and chronic inflammatory demyelinating polyradiculoneuropathy12,13. Sulfated glycans are highly antigenic, acting as epitopes for autoantibodies in peripheral demyelinating neuropathy12,14,15. However, complete sulfated glycan structures as well as the function of myelin glycans remain largely unknown. Moreover, the enzyme responsible for myelin sulfation remains to be identified.

In this study, we found that GlcNAc-6-O-sulfated N-glycans are highly conserved and abundant in PNS myelin among mammals. GlcNAc-6-O-sulfotransferase-1 (GlcNAc6ST-1) deficiency in mice resulted in a lack of sulfated N-glycans, and caused abnormal myelination and axonal degeneration in the PNS. These results suggest that the 6-O-sulfation of the GlcNAc residue by GlcNAc6ST-1 is critical for normal PNS myelination.

Results

Anionic N-glycans are highly abundant in PNS myelin compared to CNS myelin. We developed a systematic method to purify and analyze N-glycans from small tissue samples16,17. Moreover, our method is highly effective at analyzing water-insoluble samples including myelin proteins. To determine the N-glycan profiles in PNS and CNS myelin, both types of myelin were purified from porcine peripheral spinal roots and spinal cords, respectively. Purified N-glycans from PNS and CNS myelin were tagged with the fluorophore, 2-aminoypyridine18. The pyridylated (PA)-N-glycans were then analyzed by high performance liquid chromatography (HPLC) using an anion exchange DEAE column, which separates sugar chains based on their negative charge (Fig. 1A). Neutral N-glycans are first eluted in the non-adsorbed fraction, and then anionic N-glycans are eluted in subsequent fractions. The amount of N-glycan was measured as the peak area in the HPLC chromatograms. As compared with porcine CNS myelin, porcine PNS myelin contained abundant anionic N-glycans harbored on glycoproteins (Fig. 1B).

To examine which glycoproteins harbor anionic N-glycans in PNS myelin, we focused on P0 protein, as glycoprotein P0 is the most abundant PNS protein accounting for 20% to over 50% of the total protein within PNS myelin18,19. P0 protein was purified from porcine PNS myelin by immobilized metal ion adsorption chromatography20, from which N-glycans were released and purified. PA-N-glycans from P0 protein were analyzed by DEAE HPLC (Fig. 1C). The N-glycan elution profile from P0 protein was similar to that from PNS myelin, and the retention times for major peaks 1–4 from P0 protein were identical to those from PNS myelin.

Major N-glycans from bovine PNS myelin have been reported21–23, and the N-glycan elution profile from bovine PNS myelin by DEAE HPLC was similar to that from porcine PNS myelin (Supplementary Fig. S1A). To identify porcine peak 1–4 N-glycans, the anionic fractions of peaks 1–4 from P0 protein were individually collected and further analyzed by reverse-phase (RP) HPLC (Fig. 1D–G). The four major N-glycans in bovine PNS myelin, GP3-5 and OPPE1, were used as standard sugar chains, and the N-glycans of main peaks 1’, 2’, 3’, and 4’ were identified as sulfated N-glycans, GP3, GP4, OPPE1, and GP5 (Fig. 1H). Thus, both porcine and bovine PNS myelin have abundant anionic N-glycans on their glycoproteins, especially sulfated N-glycans, compared to CNS myelin. In porcine PNS myelin, N-glycans on the most abundant protein P0 are highly sulfated.

GlcNAc-6-O-sulfation of N-glycans in PNS myelin is highly conserved across mammalian species. We next examined N-glycan profiles in mouse PNS and CNS myelin by DEAE HPLC (Fig. 2A and Supplementary Fig. S1B). Mouse PNS myelin had abundant anionic N-glycans, similar to porcine PNS myelin, while little anionic N-glycans were detected in mouse CNS myelin. The N-glycan elution profile of rat sciatic nerves was similar to that from mouse PNS myelin (Supplementary Fig. S1C). It is noteworthy that the anionic N-glycan elution profile from mouse PNS myelin was less similar to that from porcine PNS myelin (Figs 1A and 2A). To identify major peak 5–9 N-glycans from mouse PNS myelin, the anionic fractions of these peaks were individually collected and further analyzed. After desialylation (peaks 5 and 6 in Fig. 2A, Supplementary Fig. S2A and S2B) and desulfation (peaks 7 and 8 and 9 in Fig. 2A, Supplementary Fig. S2C and S2D), the N-glycans from peaks 5–9 became neutral and were analyzed by normal-phase (NP) HPLC (Fig. 2B–E). The N-glycans of the major peaks were further analyzed and identified by RP-HPLC, and their elution times were compared with those of known standards (Supplementary Fig. S3). The N-glycan structures from peaks 5–6 are shown in Fig. 2F (for details see Methods). The amount of sulfated N-glycans was calculated. As compared with mouse CNS myelin, mouse PNS myelin contained highly abundant sulfated N-glycans on glycoproteins (Fig. 2G).

The structure of the main N-glycans in the neutral fraction from mouse PNS myelin in Fig. 2A was determined, and is shown in Supplementary Fig. S4 (for details see Methods).

GlcNAc6ST-1 sulfates N-glycans in mouse PNS myelin. Even though the precise sulfated N-glycan structures in mouse PNS myelin are not the same as those in porcine PNS myelin (e.g., there is a different sialyl linkage between GP4 in Fig. 1H and i in Fig. 2F), the 6-O-sulfation at the GlcNAc residue on the N-glycans is highly conserved between pig and mouse PNS myelin. The sulfation modification at the C6 position of the GlcNAc residue (GlcNAc-6-O-sulfation) is mediated by GlcNAc6STs, and four members of the GlcNAc6ST family have been cloned in mice26–28. We examined the transcript expression of GlcNAc6STs by reverse transcription (RT)-PCR in 12-week-old mouse PNS myelin (Fig. 2H). GlcNAc6ST-1 mRNA was detected in mouse sciatic nerves, whereas mRNAs encoding GlcNAc6ST-2, 3 and 4 were not detected in our experimental conditions.
Additionally, GlcNAc6ST-1 mRNA was detected in the mouse CNS at a comparable amount to that in the PNS (Supplementary Fig. S5).

To examine whether GlcNAc6ST-1 catalyzes 6-O-sulfation of GlcNAc on N-glycans in PNS myelin, N-glycans from GlcNAc6ST-1-knockout (KO) mouse PNS myelin were analyzed by DEAE HPLC. Sulfated N-glycans (peaks 7–9) from PNS myelin of young adult (Fig. 2I) and adult (Supplementary Fig. S6) GlcNAc6ST-1-null mice were not detected, whereas the levels of non-sulfated sialyl N-glycans (peaks 5 and 6) were increased compared to wild-type (WT) (Fig. 2J). N-glycans of peaks 5 and 6 were desulfated forms of peaks 7–9 (Fig. 2F). These results indicate that GlcNAc6ST-1 sulfates N-glycans, and there is no compensation mechanism for the GlcNAc-6-O-sulfation of N-glycans in mouse PNS myelin.

**N-glycans on P0 protein are not sulfated in the CNS.** Proteolipid protein (PLP) is an abundant protein found in CNS myelin, and replaced P0 as the major CNS myelin structural protein during CNS myelin evolution. The myelin compaction phenotype in PLP-null mice was rescued by transgene expression of P0 protein (P0-CNS mice), but the axonal degeneration phenotype was exaggerated in P0-CNS mice. To determine the glycosylation profile of P0 protein in CNS myelin, we analyzed N-glycans in CNS myelin from P0-CNS mice (Supplementary Fig. S7). Since P0 was expressed as a major protein in the CNS myelin of P0-CNS mice, the N-glycan expression profile would be affected if the N-glycans on P0 proteins were sulfated as in PNS myelin.

**Figure 1. Sulfated N-glycans are abundant in porcine PNS and on P0 protein.** (A) PA-N-glycans from porcine CNS (blue) and PNS (red) myelin were separated using a DEAE column. Peaks 1–4 were numbered in order of elution time for the anionic fractions. The asterisk indicates the peak derived from contaminants. Arrowheads indicate the elution positions of mono-, di-, tri-, and tetra-sialyl standard PA-oligosaccharides. (B) The percentages of neutral and anionic N-glycans from porcine CNS and PNS myelin were measured as the peak areas on DEAE HPLC; n = 4 for each group. Error bars indicate the mean ± SD. (C) PA-N-glycans from purified porcine P0 protein were separated using a DEAE column. The elution positions of peaks 1–4 coincided with those from porcine CNS myelin. The peak 1–4 fractions were collected individually. (D–G) The anionic fractions of peaks 1 (D), 2 (E), 3 (F) and 4 (G) from P0 protein were individually analyzed by RP-HPLC. Main peaks 1′ (D), 2′ (E), 3′ (F) and 4′ (G) were numbered. (H) The N-glycans of peaks 1′–4′ in Fig. 1D–G were identified as sulfated N-glycans. All structures are shown as pyridylaminated (PA-) forms.
Figure 2. GlcNAc6ST-1 exclusively catalyzes sulfation of N-glycans in mouse PNS myelin. (A) PA-N-glycans from young adult mouse PNS myelin were analyzed by DEAE HPLC. Peaks 5–9 were numbered in order of elution time from the anionic fractions. The elution positions of peaks 5 and 6 were mono- and di-sialyl N-glycans, respectively. The peak 5–9 fractions were collected and further analyzed individually. The asterisk indicates the peak derived from contaminants. Arrowheads indicate the elution positions of mono-, di-, tri-, and tetra-sialyl standard PA-oligosaccharides. (B–E) The anionic fractions of peaks 5 (B), 6 (C), 7 + 8 (D) and 9 (E) from mouse PNS myelin were individually analyzed by NP-HPLC after desialylation (peaks 5 and 6) and desulfation (peaks 7 + 8 and 9). The major peaks 5a, 5b, 5c (B), 6′ (C), (7 + 8)i, (7 + 8)ii (D) and 9′ (E) were numbered. (F) The N-glycans of peaks 5a, 5b, 5c (B), 6′ (C), (7 + 8)i, (7 + 8)ii (D) and 9′ (E) in Fig. 2B–E were further analyzed (Supplementary Fig. S3), and the N-glycan structures from peaks 5–6 were identified. (G) The percentages of sulfated N-glycans from mouse CNS and PNS myelin were measured. Error bars indicate the mean ± SD (CNS myelin, n = 4; PNS myelin, n = 7). (H) The mRNA expression levels of four GlcNAc6STs in sciatic nerves were analyzed by RT-PCR. (I) PA-N-glycans from PNS myelin of young adult GlcNAc6ST-1-KO mice (red) were separated using a DEAE column. The elution positions of peaks 5–8 coincided with those from PNS myelin of WT mice (black; Fig. 2A). (J) The percentages of N-glycans from PNS myelin of young adult WT and GlcNAc6ST-1-KO mice were measured as the peak areas on DEAE HPLC. Error bars indicate the mean ± SD (WT mice, n = 7; GlcNAc6ST-1-KO mice, n = 3).
DEAE HPLC elution profile of N-glycans in CNS myelin from P0-CNS mouse brains was similar to that from WT and PLP-null mouse brains. The N-glycans forming the major peaks in the anionic fraction from mouse brains were sialylated but not sulfated as described previously. These results suggest that N-glycans on P0 protein are not sulfated when P0 is expressed in CNS myelin.

GlcNAc6ST-1-KO mice display abnormal myelination and axonal degeneration in the PNS. Peripheral nerves of P0-KO mice are characterized by severe hypomyelination and axonal degeneration. Myelinated axons are segregated into distinct domains that include the nodes of Ranvier and their flanking paranodal regions. To investigate the role of sulfated N-glycans in the PNS, longitudinal sections of sciatic nerves from WT and GlcNAc6ST-1-KO mice were immunostained using antibodies against Caspr, a paranodal marker. The lengths of the paranodal regions and the nodal gaps between paranodes were elongated in GlcNAc6ST-1-KO mice compared to WT mice. Thus, GlcNAc6ST-1 deficiency in mice causes abnormal myelin structures. These results indicate that GlcNAc6ST-1 modulates myelination in the PNS.

We next stained transverse semi-thin sections of sciatic nerves from 18-week-old young adult WT and GlcNAc6ST-1-null mice with toluidine blue. GlcNAc6ST-1-null mice displayed axonal degeneration in the sciatic nerves. We also measured the g-ratios (axon diameters/fiber diameters) of myelinated axons, and found that the average g-ratio in young adult GlcNAc6ST-1-null mice was significantly increased. These results indicate that GlcNAc6ST-1 deficiency in young adult mice causes abnormal myelination and axonal degeneration.

Ultrastructure of GlcNAc6ST-1-KO sciatic nerves. The abnormal morphology in sciatic nerves of GlcNAc6ST-1-KO mice was further investigated using serial block face-scanning electron microscopy (SBF-SEM) to acquire serial electron microscopic images. Among normal appearing axons, some myelinated axons of adult GlcNAc6ST-1-null mice had vacuolar structures between the myelin sheath and axolemma, and showed abnormal thinning of the axoplasm, whereas abnormal structures were not observed in those of WT mice. While paranodal loops were tightly attached to the axolemma in the normal myelinated axons, some myelinated axons of young adult GlcNAc6ST-1-KO mice showed that paranodal loops were detached from the axolemma, and outer collar and inner cytoplasmic tongue of the myelinating Schwann cell were located between the paranodal loops and the axon. These results indicate that GlcNAc6ST-1 deficiency in mice leads to abnormal morphology in the PNS.

Discussion
In the present study we showed that GlcNAc6ST-1 almost exclusively catalyzes sulfation of N-glycans on glycoproteins in mouse PNS myelin. We further found that GlcNAc6ST-1 modulates myelination and myelinated axonal survival in the mouse PNS. Surprisingly, GlcNAc-6-O-sulfated N-glycans are abundant and well conserved in mammalian PNS myelin, whereas levels of sulfated N-glycans are generally very low, as described for CNS myelin. Therefore, sulfated N-glycans play important roles in the PNS.
A unique sulfated glycan structure, human natural killer-1 (HNK-1), is a sulfated glucuronic acid attached to the non-reducing terminal of an N-acetyllactosamine residue, and one of the epitopes for autoantibodies in peripheral demyelinating neuropathy. The HNK epitope is reported to be present in variable amounts, with little or no presence in rodents, and much higher levels in bovine and human PNS myelin. Our results on the amount of HNK-1-containing glycans (Figs 1 and 2 and Supplementary Fig. S1) are consistent with these previous reports. However, we also demonstrated that the GlcNAc-6-O-sulfation of N-glycans on glycoproteins was highly conserved in PNS myelin between rodents and other mammals. Therefore, our results suggest that GlcNAc-6-O-sulfated N-glycans share a common key role in PNS myelination among mammals, and HNK-1-containing glycans may perform a specific function in human, porcine and bovine PNS myelin.

Defects in Schwann cell genes can cause dysmyelinating peripheral neuropathies, which can include axonal degeneration. Here we showed that loss of sulfated N-glycans by GlcNAc6ST-1 deficiency results in abnormal myelination and axonal degeneration in the PNS (Figs 3, 4, 5, and 6). P0 protein is a Schwann cell-specific glycoprotein with a single N-glycosylation site, and is the most abundant PNS myelin protein. P0 protein contributes to the formation and maintenance of myelin compaction by homophilic interactions, and the glycosylation of P0 protein is essential for homophilic adhesion. A point mutation in the glycosylation site of P0 protein abolishes P0 glycosylation. However, GlcNAc6ST-1 deletion inhibited only GlcNAc-6-O-sulfation, whereas the N-glycan backbone structure was maintained (Fig. 2F and J). P0 protein carrying high-mannose type sugar residues has been shown to be non-adhesive. We demonstrated that the sulfated N-glycan on P0 protein is a hybrid or complex type glycan, not a high-mannose type glycan (Fig. 1C and H). We propose that sulfated N-glycans on P0 proteins stabilize compact PNS myelin via homophilic adhesion, though we cannot exclude the possibility that other myelin proteins with sulfated N-glycans are involved in myelination.

Charcot-Marie-Tooth (CMT) disease is the most common inherited disorder of the PNS, and CMT type 1B is caused by over 200 mutations in the gene encoding P0 protein. Patients with P0 protein mutations near the glycosylation site develop an axonal CMT (CMT2), and patients with P0 protein mutations at the glycosylation site develop a demyelinating CMT (CMT1B). P0-null mice display severe hypomyelination and axonal degeneration in the PNS. Mouse PNS demyelination induced by intraneural injection of lyssolecithin showed elongated Caspr immunostaining. Sural nerve biopsies from patients with hereditary neuropathies had similar elongated Caspr immunostaining. We also found that PNS...
nerves from GlcNAc6ST-1-null mice displayed elongated Caspr immunostaining and axonal degeneration (Figs 3 and 4). These results suggest that depletion of GlcNAc6ST-1 reduces PNS myelin compaction and alters paranodal structures (Fig. 6). Subsequently, the lack of Schwann cell support causes axonal degeneration. Therefore, GlcNAc6ST-1 may be involved in the pathogenesis of peripheral neuropathy.

With the appearance of reptiles/aves, the function of PLP became fully established, allowing the silent dropout of P₀ from CNS myelin^{29,30}. In fish, P₀ protein mediates both CNS and PNS myelin compaction^{29,30}. Moreover, N-glycans on fish P₀ in both CNS and PNS myelin are sulfated^{50}. It would be interesting to identify and compare N-glycans on fish P₀ in the CNS and PNS from an evolutionary point of view. When PLP was experimentally replaced by P₀ in mouse CNS myelin, this PLP-P₀ shift resulted in degeneration of myelinated axons, severe neurological disability, and reduced myelin internode length, whereas PLP/P₀-CNS mice containing PLP and P₀ do not seem to develop these phenotypes and pathologies^{31}. Although GlcNAc6ST-1 is present and active in producing keratan sulfate in the mouse CNS^{26,31,32} (Supplementary Fig. S5), P₀ protein in CNS myelin does not seem to harbor sulfated N-glycans in P₀-CNS mice (Supplementary Fig. S7). These results thus suggest that GlcNAc6ST-1 is involved in the synthesis of keratan sulfate in the CNS, but not toward N-glycan sulfation. It is possible that there are different mechanisms by which GlcNAc6ST-1 recognizes substrates between the mouse CNS and PNS. Further studies are necessary to address this issue.

Figure 5. Abnormal axonal morphology and disorganized paranodes of myelinated axons in GlcNAc6ST-1-KO mice revealed by serial image acquisition with SBF-SEM. (A–D) One of serial images of GlcNAc6ST-1-KO (A) and 3D reconstructions of WT (C) and GlcNAc6ST-1-KO (B,D) sciatic nerves. There were vacuolar structures (red, arrowheads) between the myelin sheath and axolemma in the myelinated axons (blue, white arrow) of GlcNAc6ST-1-KO mice (A). 3D reconstructions show abnormal thinning of axoplasm in the axons of GlcNAc6ST-1-KO mice (arrows, D). Ax, axon. Scale bars: 20 μm. (E–I) In the normal myelinated axons (E,F), paranodal loops (arrowheads, variously colored, F) were tightly attached to the axolemma. In the myelinated axons of GlcNAc6ST-1-KO mice (G–I), paranodal loops were detached from the axolemma. The outer collar (arrow, blue, H) and inner cytoplasmic tongue (white arrow, green, I) of the myelinating Schwann cell were located between the paranodal loops and the axon. My: compact myelin. Areas indicated with rectangles (E,G) are magnified (F,H,I). Scale bars: 1 μm.
Taken together, our results support a model where GlcNAc6ST-1 regulates PNS myelination through sulfation of N-glycans on P0 protein. Our findings may provide novel insights into the pathogenesis of peripheral neuropathy.

Methods
Detailed procedures and reagent information are presented in the Supplementary Information.

Animals. All experimental procedures were approved by the Animal Care and Use Committee of National Institute for Physiological Sciences and Nagoya University Graduate School of Medicine, and conducted in accordance with the Guidelines and Regulations for the Care and Use of Experimental Animals by National Institute for Physiological Sciences and Nagoya University Graduate School of Medicine. GlcNAc6ST-1-KO, P0-CNS and PLP-null mice were generated as described previously. Wistar rats and 10–18-week-old young adult and 30–33-week-old adult ICR mice were purchased from Japan SLC (Hamamatsu, Japan).

Purification of myelin fractions and P0 protein. Purification of myelin fractions and P0 protein was performed as described previously. Additional details are provided in the Supplementary Information.

N-glycan purification, pyridylamination, and analysis for identification. N-glycan purification and pyridylamination were performed as described previously. PA-N-glycans were analyzed by HPLC using the following columns: DEAE (TSKgel DEAE-5PW, Tosoh, Tokyo, Japan), NP (Shodex Asahipak NH2P-50 4E, Showa Denko, Tokyo, Japan) and RP (CAPCELL PAK C18 SG120, Shiseido, Tokyo, Japan or Develosil C30-UG-5, Nomura Chemical, Seto, Japan). Additional details are provided in the Supplementary Information.

Immunofluorescence studies. Immunostaining was performed as described previously. Additional details are provided in the Supplementary Information.

Morphological studies. After the sciatic nerves were fixed, dehydrated and embedded, cross-sections of 0.7 μm thickness were cut and stained with 0.5% toluidine blue. Sections were observed using a light microscope. Additional details are provided in the Supplementary Information.

SBF-SEM imaging and analyses. The imaging and 3D ultrastructural analyses were performed as described previously. Additional details are provided in the Supplementary Information.

Statistics. Statistical significance was determined by unpaired, two-tailed Student's t-tests. P-values of <0.05 were considered statistically significant. Data were collected and processed randomly, and were analyzed using Microsoft Excel.

References
1. Sherman, D. L. & Brophy, P. J. Mechanisms of axon ensheathment and myelin growth. Nat. Rev. Neurosci. 6, 683–690 (2005).
2. Susuki, K. & Rasband, M. N. Molecular mechanisms of node of Ranvier formation. Curr. Opin. Cell Biol. 20, 616–623 (2008).
3. Eshed-Eisenbach, Y. & Peles, E. The making of a node: a co-production of neurons and glia. Curr. Opin. Neurobiol. 23, 1049–1056 (2013).
4. Nave, K. A. & Werner, H. B. Myelination of the nervous system: mechanisms and functions. Annu. Rev. Cell Dev. Biol. 30, 503–533 (2014).
5. Fields, R. D., Woo, D. H. & Basser, P. J. Glial Regulation of the Neuronal Connectome through Local and Long-Distant Communication. Neuron 86, 374–386 (2015).
6. Nave, K. A. & Trapp, B. D. Axon-glia signalling and the glial support of axon function. Annu. Rev. Neurosci. 31, 535–561 (2008).
7. Quares, R. H. Myelin sheaths: glycoproteins involved in their formation, maturation and degeneration. Cell. Mol. Life Sci. 59, 1851–1871 (2002).
8. Quares, R. H. Comparison of CNS and PNS myelin proteins in the pathology of myelin disorders. J. Neural. Sci. 228, 187–189 (2005).
9. Poliak, S. & Peles, E. The local differentiation of myelinated axons at nodes of Ranvier. Nat. Rev. Neurosci. 4, 968–980 (2003).
10. Varki, A. Evolutionary forces shaping the Golgi glycosylation machinery: why cell surface glycans are universal to living cells. Cold Spring Harb. Perspect. Biol. 3, a005462 (2011).
11. Gagneux, P. & Varki, A. Evolutionary considerations in relating oligosaccharide diversity to biological function. Glycobiology 9, 747–755 (1999).
12. Kaida, K., Ariga, T. & Yu, R. K. Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders–a review. Glycobiology 19, 676–692 (2009).
13. Stathopoulos, P., Alexopoulos, H. & Dalakas, M. C. Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders. Nat. Rev. Neurol. 11, 143–156 (2015).
14. Chou, D. K. et al. Structure of sulfated glucuronyl glycolipids in the nervous system reacting with HNK-1 antibody and some IgM paraproteins in neuropathy. J. Biol. Chem. 261, 11717–11725 (1986).
15. Kizuka, Y. & Oka, S. Regulated expression and neural functions of human natural killer-1 (HNK-1) carbohydrate. Cell. Mol. Life Sci. 69, 4133–4147 (2012).
16. Yoshimura, T. et al. Detection of N-glycans on small amounts of glycoproteins in tissue samples and sodium dodecyl sulfate-polyacrylamide gels. Anal. Biochem. 423, 253–260 (2012).
17. Tori, T. et al. Determination of major sialylated N-glycans and identification of branched sialylated N-glycans that dynamically change their content during development in the mouse cerebral cortex. Glycoconj. J. 31, 671–683 (2014).
18. Greenfield, S., Brostoff, S., Eylar, E. H. & Morell, P. Protein composition of myelin of the peripheral nervous system. J. Neurochem. 20, 1207–1216 (1973).
19. Patzig, I. et al. Quantitative and integrative proteome analysis of peripheral nerve myelin identifies novel myelin proteins and candidate neuropathy loci. J. Neurosci. 31, 16369–16386 (2011).
20. Medzihradszky, K., Stanko, Z. & Milanović, M. Glycoconjugates of the peripheral nervous system. Glycobiology 24, 87–100 (2014).
21. Uyemura, K., Kitamura, K. & Miura, M. Structure and molecular biology of P0 protein. In Greenfield, S., Brostoff, S., Eylar, E. H. & Morell, P. (eds) Protein composition of myelin of the peripheral nervous system. J. Neurochem. 20, 1207–1216 (1973).
22. Kitamura, K. et al. Structure of a major oligosaccharide of PASII/PMP22 glycoprotein in bovine peripheral nerve myelin. J. Neurochem. 75, 853–860 (2000).
23. Gallego, R. G. et al. Epitope diversity of N-glycans from bovine peripheral nerve myelin glycoprotein P0 revealed by mass spectrometry and nano probe magic angle spinning 1H NMR spectroscopy. J. Biol. Chem. 276, 30834–30844 (2001).
24. Sedžik, J., Istratievski, I. P. & Grandis, M. Glycans of myelin proteins. J. Neurosci. Res. 93, 1–18 (2015).
25. Wu, C.-Y. et al. Molecular cloning and characterization of an O-acetylglucosamine-6-O-sulfotransferase. J. Biol. Chem. 273, 2557–2563 (1998).
26. Hamerich, K. & Rosen, S. Carbohydrate sulfotransferases in lymphocyte homing. Glycoconjug. J. 10, 849–856 (2000).
27. Fukuda, M., Hiraoaka, N., Akama, T. O. & Fukuda, M. N. Carbohydrate-sulfating sulfotransferases: structure, function, and pathogenesis. J. Biol. Chem. 276, 47747–47750 (2001).
28. Wachenhfeldt, T. V. Phylogeny of myelin proteins. Annu. N. Y. Acad. Sci. 605, 15–28 (1990).
29. Yoshida, M. & Colman, D. R. Parallel evolution and coexpression of the proteolipid proteins and protein zero in vertebrate myelin. Neuron 16, 1115–1126 (1996).
30. Yin, X. et al. Evolution of a neuroprotective function of central nervous system myelin. J. Cell. Biol. 172, 469–478 (2006).
31. Giese, K. P., Martini, R., Lembre, G., Soriano, P. & Schachner, M. Mouse P0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons. Cell 71, 565–576 (1992).
32. Martini, R. P0-deficient knockout mice as tools to understand pathomechanisms in Charcot-Marie-Tooth 1B and P0-related Dejérine-Sottas syndrome. Annu. N. Y. Acad. Sci. 883, 273–280 (1999).
33. Einheber, S. et al. The axonal membrane protein Caspr, a homologue of nucleolin IV, is a component of the septate-like paranodal junctions that assemble during myelination. J. Cell. Biol. 139, 1495–1506 (1997).
34. Yagi, H. & Kato, K. Multidimensional HPLC mapping method for the structural analysis of anionic N-glycans. Trends Glycosci. Glycobiol. 21, 95–104 (2009).
35. Mattthieu, J. M., Quares, R. H., Poduslo, J. F. & Brady, R. O. [35-S]-sulfate incorporation into myelin glycoproteins: I. Central nervous system. Biochim. Biophys. Acta. 392, 159–166 (1975).
36. Mattthieu, J. M., Everly, I. L., Brady, R. O. & Quares, R. H. [35-S]-sulfate incorporation into myelin glycoproteins: II. Peripheral nervous tissue. Biochim. Biophys. Acta. 392, 167–174 (1975).
37. O’Shannessy, D. J., Willson, H. J., Inuzuka, T., Dobersen, M. J. & Quares, R. H. The species distribution of nervous system antigens that react with anti-myelin-associated glycoprotein antibodies. J. Neuroimmunol. 9, 255–268 (1985).
38. Levy, A. D., Guérard, V., Aebischer, P. & Bunge, R. P. The functional characteristics of Schwann cells cultured from human peripheral nerve after transplantation into a gap within the rat sciatic nerve. J. Neurosci. 14, 1309–1319 (1994).
39. Smith, M. E. Sulfate metabolism of rat P0 glycoprotein: some observations. Neurochem. Res. 19, 1039–1045 (1994).
40. Shy, M. E. Peripheral neuropathies caused by mutations in the myelin protein zero. J. Neurol. Sci. 242, 55–66 (2006).
41. Filbin, M. T., Walsh, F. S., Trapp, B. D., Pizzey, J. A. & Tennekeko, G. I. Role of myelin P0 protein as a homophilic adhesion molecule. Nature 344, 871–872 (1990).
42. Filbin, M. T. & Tennekeko, G. I. The role of complex carbohydrates in adhesion of the myelin protein, P0. Neuron 7, 845–855 (1991).
43. Filbin, M. T. & Tennekeko, G. I. Homophilic adhesion of the myelin P0 protein requires glycosylation of both molecules in the homophilic pair. J. Cell Biol. 122, 451–459 (1993).
44. Brennan, K. M., Bai, Y. & Shy, M. E. Demyelinating CMT-what’s known, what’s new and what’s in store? Neurosci. Lett. 596, 14–26 (2015).
45. Szigeti, K., Nelis, E. & Lupski, J. R. Molecular diagnostics of Charcot-Marie-Tooth disease and related peripheral neuropathies. Neuromolecular Med. 8, 243–254 (2006).
46. Suzuki, K. Node of Ranvier dysfunction as a cause of neurological diseases. ASN Neuro 5, 209–219 (2013).
47. Li, J. et al. Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. Brain 128, 1168–1177 (2005).
48. Bai, Y. et al. Effect of an R69C mutation in the myelin protein zero gene on myelination and ion channel subtypes. Arch. Neurol. 63, 1787–1794 (2006).
49. Hammer, J. A. et al. Immunoreactivity of PMP-22, P0, and other 19 to 28 kDa glycoproteins in peripheral nerve myelin of mammals and fish with HNK1 and related antibodies. J. Neurosci. Res. 35, 546–558 (1993).
50. Zhang, Y. et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 34, 11929–11947 (2014).
52. Takeda-Uchimura, Y. et al. Requirement of keratan sulfate proteoglycan phosphacan with a specific sulfation pattern for critical period plasticity in the visual cortex. *Exp. Neurol.* **274**, 145–155 (2015).

53. Uchimura, K. et al. N-acetylglucosamine 6-O-sulfotransferase-1 regulates expression of L-selectin ligands and lymphocyte homing. *J. Biol. Chem.* **279**, 35001–35008 (2004).

54. Sedzik, J., Kotake, Y. & Uyemura, K. Purification of P0 myelin glycoprotein by a Cu^{2+}-immobilized metal affinity chromatography. *Neurochem. Res.* **24**, 723–732 (1999).

55. Yamaguchi, Y., Miyagi, Y. & Baba, H. Two-dimensional electrophoresis with cationic detergents, a powerful tool for the proteomic analysis of myelin proteins. Part 1: technical aspects of electrophoresis. *J. Neurosci. Res.* **86**, 755–765 (2008).

56. Yamaguchi, Y., Miyagi, Y. & Baba, H. Two-dimensional electrophoresis with cationic detergents: a powerful tool for the proteomic analysis of myelin proteins. Part 2: analytical aspects. *J. Neurosci. Res.* **86**, 766–775 (2008).

57. Hayashi, A., et al. Localization of annexin II in the paranodal regions and Schmidt-Lanterman incisures in the peripheral nervous system. *Glia* **55**, 1044–1052 (2007).

58. Nguyen, H. B. et al. Conductive resins improve charging and resolution of acquired images in electron microscopic volume imaging. *Sci. Rep.* **6**, 23721 (2016).

59. Thar, T. Q., et al. Rapid specimen preparation to improve the throughput of electron microscopic volume imaging for three-dimensional analyses of subcellular ultrastructures with serial block-face scanning electron microscopy. *Med. Mol. Morphol.* **49**, 154–162 (2016).

**Acknowledgements**

We thank: Drs. K. Susuki (Wright State University), K. Menon (Amrita Institute of Medical Sciences), H. Hashimoto (National Institute for Physiological Sciences) and M.N. Rasband (Baylor College of Medicine) for helpful discussion; Ms. I. Itoh and Mr. Y. Kano for preparing materials and technical assistance; Ms. A. Kawakami, Ms. H. Yoshida, Ms. E. Akasaka and Ms. M. Tanaka for secretarial assistance; the Functional Genomics Facility in the National Institute for Basic Biology for use of equipment. This work was supported in part by Grants-in-Aid for Young Scientists (B) and Research Activity start-up from Japan Society for the Promotion of Science (JSPS), KAKENHI Grant Number 21700420 (to T.Y.), 16K18977 (to N.O.) and 15H06840 (to T.Y.); Grants-in-Aid for Scientific Research on Innovative Areas “glial assembly” (No. 25117005 to K.I.), “neuro-glycoscience” (No. 26110716 to H.Y. and 23110002 to K.Kad.) and “dynamical ordering and integrated functions” (No. 25102008 to K.Kat.) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; R35NS097303 from NINDS, NIH (to B.D.T.); the Japan-United States Brain Research Cooperative Program (to T.Y.); the Cooperative Study Programs of National Institute for Physiological Sciences (to H.B.); and NINS program for cross-disciplinary study.

**Author Contributions**

T.Y. and K.I. designed the research; T.Y., A.H., M.H.-N., N.O., T.K., Y.Y. and J.S. performed the research; K.U., K.Kad. and B.D.T. provided crucial reagents, mice and support; H.Y., K.Ki. and K.Kat. contributed new reagents/analytic tools; T.Y., M.H.-N., A.H. and H.B. analyzed the data; T.Y., B.D.T. and K.I. wrote the paper; all authors discussed the results and commented on the manuscript.

**Additional Information**

Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Yoshimura, T., et al. GlcNAc6ST-1 regulates sulfation of N-glycans and myelination in the peripheral nervous system. *Sci. Rep.* **7**, 42257; doi: 10.1038/srep42257 (2017).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2017